A113 SIONS: Medical treatment costs in the year after initiation on duloxetine decreased by a greater amount among duloxetine patients with greater persistence compared to those who discontinued early. The findings underscore the importance of sufficient length of therapy for major depressive disorder.
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Bristol Myers Squibb, D.F., Mexico, 2 Bristol-Myers Squibb Co, Wallingford, CT, USA OBJECTIVES: The overall cost of care for patients with schizophrenia can increase considerably, due to management of diseases related to the metabolic syndrome such as coronary heart disease (CHD) and diabetes. In the STAR study, aripiprazole is a second-generation antipsychotic that has shown relatively less adverse metabolic effects than other antipsychotics. The objective of this study is to estimate the avoided cost of CHD and diabetes with the use of aripiprazole compared with the standard of care (SOC) treatment (olanzapine, quetiapine and risperidone) in Mexico. METHODS: Predictions of avoided diabetes and CHD for patients receiving aripiprazole or SOC were based on risk factor data on metabolic outcomes from the STAR study and related published articles. These calculations were applied to the Mexican population considering a schizophrenia prevalence of 0.7%. The annual cost per patient for the treatment of diabetes and CHD in Mexico was obtained from the literature review indexed to 2009 prices using the national consumption index for health. Cost calculations were discounted by an annual rate of 3.5% and expressed in US dollars at an exchange rate of $13.53 Mexican pesos per dollar. RESULTS: The estimated number of avoided cases of diabetes and CHD were of 23.4 and 3.7 per 1000 treated patients with aripiprazole compared with SOC. If patients were treated with aripiprazole as the first agent, the accumulated direct avoided costs over a 10 year period for diabetes would be of US$10 millions and for CHD would be of US$17 million. This represents total accumulated savings for the Mexican Health Care system of US$27 millions during this period. CONCLUSIONS: Usage of aripiprazole in the Mexican Health Care system can be translated into a significant reduction of health care costs due to the favorable metabolic profile of this drug when compared to SOC.
PMH48 VALIDATING A COST-EFFECTIVENESS ANALYSIS COMPARING OLANZAPINE WITH ZIPRASIDONE IN THE TREATMENT OF SCHIZOPHRENIA
Graham C 1 , Mauskopf J 1 , Lawson AH 2 , Ascher-Svanum H 2 , Bruhn D 2 , Watson PR 2 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: A new cost-effectiveness model, using head-to-head data, was developed to validate results from a prior indirect analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia from the perspective of a third-party payer in the United States. METHODS: A decision analytic modeling approach was used to estimate the annual medical costs and health outcomes associated with treatment of schizophrenia with the 2 comparators. The decision-tree structure included branches representing key clinical events such as response, relapse, and suicide attempts/completion. Patients without response to first-line treatment switched to the other comparator. Decision-tree probabilities were extracted from a head-to-head study and other published clinical literature. Direct medical costs and quality-adjusted life years (QALYs) were estimated based on resource use (inpatient, outpatient, suicide, and drug costs) and utility weights for initial and relapse episodes, maintenance therapy, and extended episodes of schizophrenia. Disutilities associated with adverse events (extrapyramidal symptoms [EPS], we ight gain, and hypotension) were also considered. One-way and probabilistic sensitivity analyses were performed. RESULTS: First-line treatment with olanzapine was associated with fewer hospital days, fewer EPS days, and greater number of QALYs than first-line treatment with ziprasidone. Drug costs were higher for the olanzapine pathway; however, total costs were lower for the olanzapine pathway than the ziprasidone pathway due to cost savings associated with better health outcomes and less medical resource use. The incremental cost per QALY gained indicated that the olanzapine pathway dominated the ziprasidone pathway. The one-way and probabilistic sensitivity analyses confirmed the robustness of the model and its results. CONCLUSIONS: The model confirms results of the previous model and indicates that olanzapine is associated with better expected health outcomes and lower costs than ziprasidone. Despite a potential increase in drug costs, treating schizophrenia with olanzapine instead of ziprasidone could lead to cost savings for payers in the United States.
PMH49

COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
Taneja C 1 , Oster G 1 , Jing Y 2 , Baker RA 2 , Forbes RA 3 , Papakostas GI 4 1 Policy Analysis Inc., Brookline, MA, USA, 2 Bristol-Myers Squibb Company, Plainsboro, NJ, USA, 3 Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ, USA, 4 Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA OBJECTIVES: Recent approval by the US Food and Drug Administration of three atypical antipsychotics-aripiprazole, quetiapine, and olanzapine-as adjunctive therapy in adult patients with MDD makes examination of their cost-effectiveness important from a payer perspective. METHODS: We developed a decision-analytic model to estimate expected outcomes and economic costs in adults with MDD receiving aripiprazole (2-20 mg/day), quetiapine (150 mg/day or 300 mg/day), or olanzapine (6-18 mg/day as a fixed-dose combination with fluoxetine [50 mg]) as adjunctive therapy to ADT. Cost-effectiveness was assessed in terms of the ratio of the expected difference in costs of MDD-related care to the expected difference in clinical response (≥50% reduction from baseline in Montgomery-Asberg Depression Rating Scale) at 6 weeks (i.e., cost per additional responder). Expected costs of MDD-related care included study medication, and monitoring and treatment of adverse events. Model parameters were estimated using data from Phase III trials and published literature. RESULTS: With ADT alone, the expected rate of clinical response at 6 weeks was estimated to be 30%. Adjunctive therapy with aripiprazole, quetiapine 150 mg/day, quetiapine 300 mg/day, and olanzapine was estimated to increase clinical response at 6 weeks to 49%, 34%, 38%, and 45%, respectively. Costs of MDD-related care over 6 weeks were estimated to be $164 for ADT alone, $714 for aripiprazole, $498 for quetiapine 150 mg/day, $606 for quetiapine 300 mg/day, and $669 for olanzapine. Cost per additional responder (vs ADT) was estimated to be $2798 for aripiprazole, $7996 for quetiapine 150 mg/day, $5706 for quetiapine 300 mg/day, and $3324 for olanzapine. The cost-effectiveness of adjunctive therapy was most sensitive to the estimated rate of clinical response at 6 weeks and the cost of adjunctive therapy. CONCLUSIONS: Adjunctive therapy with atypical antipsychotics substantially increases clinical response at 6 weeks. Cost per additional responder is lower for aripiprazole than quetiapine or olanzapine.
PMH50 COSTS AND EFFECTS OF ILOPERIDONE COMPARED WITH OLANZAPINE AND HALOPERIDOL IN PATIENTS WITH ACUTE SCHIZOPHRENIA: RESULTS FROM A COST-EFFECTIVENESS MARKOV MODEL
Elsaid KA, Angelini M Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA OBJECTIVES: Schizophrenia is a severe chronic psychiatric disease with high treatment costs and social burden. Iloperidone is a recently FDA approved atypical antipsychotic medication for the acute treatment of adult patients with schizophrenia. The aim of this study is to compare the efficacy and cost of oral iloperidone with olanzapine and haloperidol in a cohort with acute schizophrenia over a 1 year period. METHODS: Published literature and clinical expert opinions were used to populate a Markov simulation model using TreeAge Pro 2009 software. The model consists of nine 6-week cycles. Clinical response is defined as ≥20% reduction in Positive and Negative Syndrome Scale total scores (PANSS-T) from baseline. Responders can exist in any of the following health states at the end of any cycle: Response with no adverse events (AEs), Response with mild-to-moderate AEs, Response with severe AEs, Relapse, Dropout and Suicide. Relapse is defined as an increase in PANSS-T scores ≥25% following a response period of more than 3 cycles. Efficacy was determined as the average time spent in the Response with no AEs or Response with mild-to-moderate AEs states. Direct costs included hospitalization, side effects, drugs and outpatient care costs. RESULTS: The mean time patients spent as responders with no AEs or responders with mild-to-moderate AEs was estimated to be 5.76 cycles (241.9 days) with iloperidone compared to 5.96 cycles (250.3 days) and 6.17 cycles (259.1 days) with haloperidol and olanzapine treatments, respectively. The mean monthly treatment costs were $2521, $2424 and $2292 for iloperidone, haloperidol and olanzapine, respectively. CONCLUSIONS: Using a Markov simulation model, olanzapine was more effective than either iloperidone or haloperidol with associated lower costs. Patients spent on average less time as responders with iloperidone treatment compared to haloperidol. These results may be of use when determining the most cost-effective treatment strategy for acute schizophrenia.
